Savaria initiated with an Outperform at Raymond James

Raymond James analyst Michael Glen initiated coverage of Savaria with an Outperform rating and C$21 price target. The company has a very comprehensive product line, which is split into three business segments, and Raymond James sees a combination of benefits from the Handicare acquisition from early 2021, coupled with attractive underlying thematics, the analyst tells investors in a research note.